<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03034187</url>
  </required_header>
  <id_info>
    <org_study_id>H1998-12/SFP-Prostate</org_study_id>
    <nct_id>NCT03034187</nct_id>
  </id_info>
  <brief_title>Radiation-induced Toxicity in Prostate Cancer/ Standard-Follow-Up Program Prostate</brief_title>
  <acronym>SFP-PROSTATE</acronym>
  <official_title>Radiation Induced Toxicity in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to gain insight in the development and course of the toxicity after a curative
      treatment of prostate cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All with curative intent treated prostate cancer patients will be enrolled in the SFP
      (Standard Follow-up Programme). It also includes the post -operative adjuvant treatments and
      the patients with positive lymph nodes.

      Patients will complete weekly questionnaires to score the patient -rated toxicity. Biweekly
      patients are seen by the treating radiation oncologist and / or AIOS in which the physician
      -rated toxicity is scored. In the follow-up will always patient -rated toxicity and physician
      -rated toxicity can be determined.

      Use of an SFP should yield a profit for the practitioner , such as the automatic generation
      of letters. This should apply to all SFPs .

      Quality of life and toxicity in patients will be completed on the touch-screen computers at
      FU visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. Change in Acute toxicity</measure>
    <time_frame>Toxicity:First visit/Wekely during RT, Acute Toxicity: 2-wekely and at the end of RT/ 2 months after RT/1, 2, 3, 4, 5 years after RT</time_frame>
    <description>Common Terminology Criteria for Adverse Events, version 4.0
CTCAE 4.0 Constipation
CTCAE 4.0 Diarrhea
CTCAE 4.0 Fecal Incontinence
CTCAE 4.0 Flatulance
CTCAE 4.0 Proctitis
CTCAE 4.0 Rectal Hemorrhage
CTCAE 4.0 Rectal Mucositis
CTCAE 4.0 Rectal Ulcer
CTCAE 4.0 Bladder spasm
CTCAE 4.0 Cystitis Noninfective
CTCAE 4.0 Hematuria
CTCAE 4.0 Urinary Frequency
CTCAE 4.0 Urinary Incontinence
CTCAE 4.0 Urinary retention
CTCAE 4.0 Urinary tract Obstruction
CTCAE 4.0 Urinary tract pain
CTCAE 4.0 Urinary Urgency
CTCAE 4.0 Erectile dysfunction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2. Change in patient -rated Quality-of-Life</measure>
    <time_frame>First visit/End of RT/ 2 months after RT/1, 2, 3, 4, 5 years after RT</time_frame>
    <description>Questionnarys QLQ-PR25, QLQ-C30, International Index of Erectile Function</description>
  </secondary_outcome>
  <other_outcome>
    <measure>3. Change in physiological parameters</measure>
    <time_frame>First visit/2 months after RT/1, 2, 3, 4, 5 years after RT</time_frame>
    <description>PSA and Testosteron</description>
  </other_outcome>
  <other_outcome>
    <measure>4. Change in Acute/ Late toxicity(physician rated)</measure>
    <time_frame>First Visit/ 2 wekely/ End of RT/ 2 months after RT/1, 2, 3, 4, 5 years after RT</time_frame>
    <description>Common Terminology Criteria for Adverse Events, version 4.0
CTCAE 4.0 Constipation
CTCAE 4.0 Diarrhea
CTCAE 4.0 Fecal Incontinence
CTCAE 4.0 Flatulance
CTCAE 4.0 Proctitis
CTCAE 4.0 Rectal Hemorrhage
CTCAE 4.0 Rectal Mucositis
CTCAE 4.0 Rectal Ulcer
CTCAE 4.0 Bladder spasm
CTCAE 4.0 Cystitis Noninfective
CTCAE 4.0 Hematuria
CTCAE 4.0 Urinary Frequency
CTCAE 4.0 Urinary Incontinence
CTCAE 4.0 Urinary retention
CTCAE 4.0 Urinary tract Obstruction
CTCAE 4.0 Urinary tract pain
CTCAE 4.0 Urinary Urgency
CTCAE 4.0 Erectile dysfunction</description>
  </other_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All with curative intent treated prostate cancer patients who will be treated with RT will
        be enrolled in the SFP.

        It also includes the post-surgical adjuvant treatment and patients with positive lymph
        nodes to research the development and toxicity after RT
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All curative treated patients with prostatecancer( with positive lymph nodes)

          -  All patients who will be treated with RT( including post-operative, adjuvant
             treatments)

          -  Are willing to fill in toxicity and QOL-questionnarys (QLQ-PR25 en de QLQ-C30)

        Exclusion Criteria:

        Patients who are not willing to fill in toxicity and QOL-questionnarys Patients who will
        not get RT Non-curative or palliative treated patients (with bone mestasis) Non-prostate
        cancer-patients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>A.C.M Van den Bergh, MD PhD</last_name>
    <phone>+31503611194</phone>
    <email>a.c.m.van.den.bergh@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>L.W. Kors, Msc</last_name>
    <phone>+31503617244</phone>
    <email>l.w.kors@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.C.M Van Den Bergh, MD PhD</last_name>
      <phone>+31503611194</phone>
      <email>a.c.m.van.den.bergh@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>A.C.M Van Den Bergh, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>January 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>A.C.M van den Bergh</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Acute toxicity</keyword>
  <keyword>Late toxicity</keyword>
  <keyword>Quality of Life since 2011(set-up SFP-prostate)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Sharing data between physicians at the Department of Radiotherapy</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

